Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.
July 01 2016 - 12:05PM
Business Wire
Manufacturer Offers Substantial Portfolio of
Animal Vaccines in Latin America
Merck Animal Health (known as MSD Animal Health outside the
United States and Canada) today announced it has executed an
agreement to acquire a controlling interest in Vallée S.A., a
leading privately-held producer of animal health products in
Brazil.
Vallée has an extensive portfolio of more than 100 products
spanning parasiticides, anti-infectives and vaccines. The company’s
portfolio includes products for livestock, horses, and companion
animals. Vallée was founded with the mission of producing a Foot
and Mouth Disease (FMD) vaccine for Brazil and has expanded
significantly, with distribution centers in Brazil and operations
in Paraguay, Venezuela, Mexico and Bolivia.
“Merck Animal Health has a broad portfolio of products to
protect against some of the most important pathogens affecting
livestock,” said Rick DeLuca, president, Merck Animal Health. “We
are pleased to complement our portfolio with products from Vallée,
which will further strengthen our presence in Latin America and
help us respond even more quickly and effectively to the region’s
needs.”
The agriculture industry is an important driver of the economy
in Latin America. This region contributes 11% of the value of the
world food production1 and a significant number of the cattle in
the region are vaccinated with Vallée S.A. vaccines.
“As one of the largest producers of protein in the world, Brazil
is an important market for us,” explains Ralph Cabezas, vice
president, Latin America region, Merck Animal Health. “Vallée has
been a trusted manufacturing partner in this region for a number of
years and we are pleased to offer their products to our customers
to help protect animals from diseases.”
Under terms of the agreement, Merck Animal Health, through a
subsidiary, will acquire approximately 93% of the shares of Vallée
S.A. at closing, in exchange for a payment of $400 million, based
on current exchange rates. This agreement is subject to regulatory
review and certain closing conditions.
About Merck Animal Health
For 125 years, Merck has been a global health care leader
working to help the world be well. Merck Animal Health, known as
MSD Animal Health outside the United States and Canada, is the
global animal health business unit of Merck (NYSE:MRK). Through its
commitment to the Science of Healthier Animals™, Merck Animal
Health offers veterinarians, farmers, pet owners and governments
one of the widest range of veterinary pharmaceuticals, vaccines and
health management solutions and services. Merck Animal Health is
dedicated to preserving and improving the health, well-being and
performance of animals. It invests extensively in dynamic and
comprehensive R&D resources and a modern, global supply chain.
Merck Animal Health is present in more than 50 countries, while its
products are available in some 150 markets. For more information,
visit www.merck-animal-health.com or connect with us on
LinkedIn, Facebook and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
1 Inter-American Development Bank website
http://www.iadb.org/en/topics/agriculture/latin-american-agriculture-statistics,2342.html.
Accessed on May 24, 2016.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160701005700/en/
Merck Animal HealthMedia:Amy Firsching,
+1-973-937-5453amy.firsching@merck.comorPam Eisele, +
1-267-305-3558pamela.eisele@merck.comorInvestors:Amy Klug,
+1-908-740-1898Amy.klug@merck.com
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024